Pelliciari DHS, Reis CRA, Bordini CA. Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study. Headache Med [Internet]. 2024 Sep. 30 [cited 2024 Oct. 16];15(3):170-4. Available from: https://headachemedicine.com.br/index.php/hm/article/view/1308